ISF joins efforts to support a new international initiative, specific to psoriasis, has been set up as response to the COVID-19 pandemic
PsoProtect is an international registry (i.e. a sophisticated database that will provide a real-world view health information like clinical practice, patient outcomes, safety, and comparative effectiveness) for health care providers to report outcomes of COVID-19 in individuals with psoriasis.
“The immediate purpose of the PsoProtect registry is to rapidly understand how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. We intend to provide real-time updates on cases reported for the benefit of the clinical community”, the PsoRegistry registry explains.
The registry will operate based on doctors uploading de-identified case data information through the registry’s website. The core dataset is closely aligned with that of similar efforts being undertaken for people living with inflammatory bowel disease and rheumatology to enable cross-disease analyses.
PsoProtect intends to publish regular summaries and insights from the registry, however, they are unable to provide information on request. You can follow development through their website and on Twitter.
For the most up-to-date advice on COVID-19 (Coronavirus) visit the HSE’s official site and remember to visit information from our own Covid-19 resource which we will keep updated as developments occur.
For more information about psoriasis, visit our Psoriasis Section to download our booklet, What you need to know about Psoriasis or contact the ISF Helpline for one-to-one information and support.
